Literature DB >> 16772762

Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.

Duangchit Panomvana Na Ayudhya1, Jintana Suwanmanee, Anainnit Visudtibhan.   

Abstract

The aims of this study were to define the relationship between total and unbound valproic acid (VPA) concentrations, to compare pharmacokinetic parameters of total and unbound VPA, and to determine the difference in pharmacokinetic parameters between the seizure-controlled and -uncontrolled groups. Total and unbound steady-state serum concentration of VPA were determined at trough and at 5 hours after the morning dose from 29 pediatric patients with epilepsy who were receiving valproic acid as monotherapy every 8 or 12 hours. Pharmacokinetic parameters were calculated and compared by t test (alpha=0.05). A strong relationship between total and unbound concentrations was found. The equation for predicting unbound concentration from total concentration was unbound concentration=-6.01+0.18 * total concentration (r=0.78, P<0.001). A higher percentage of free fraction was found at higher concentrations. There were significant differences between total and unbound VPA pharmacokinetic parameters. Both the elimination rate constant (Ke) and volume of distribution (Vd) of the unbound VPA were much higher than those of the total VPA; clearance (CI) was approximately 10-fold higher. The seizure-uncontrolled group could eliminate VPA much faster than the seizure-controlled group, as indicated by a much higher Ke and a much shorter t1/2 (P<0.05). Vd of the unbound VPA was also much smaller in the seizure-uncontrolled group (P<0.05). There were significant differences in pharmacokinetic parameters between seizure- controlled and -uncontrolled pediatric epileptic patients. Further study with a larger sample size is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772762     DOI: 10.1097/01.mjt.0000155113.89092.58

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  6 in total

1.  Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.

Authors:  Aaron M Cook; Muhammad S Zafar; Sally Mathias; Alejandra M Stewart; Ana C Albuja; Meriem Bensalem-Owen; Siddharth Kapoor; Robert J Baumann
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

2.  A systematic review of population pharmacokinetics of valproic acid.

Authors:  Janthima Methaneethorn
Journal:  Br J Clin Pharmacol       Date:  2018-02-28       Impact factor: 4.335

3.  A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Authors:  Christelle Rodrigues; Stéphanie Chhun; Catherine Chiron; Olivier Dulac; Elisabeth Rey; Gérard Pons; Vincent Jullien
Journal:  Eur J Clin Pharmacol       Date:  2018-03-21       Impact factor: 2.953

4.  Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.

Authors:  Dechun Jiang; Xiangrong Bai; Qingxia Zhang; Wei Lu; Yuqin Wang; Lin Li; Markus Müller
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 2.953

5.  Valproate alters dopamine signaling in association with induction of Par-4 protein expression.

Authors:  Saebom Lee; Jaehoon Jeong; Young-Un Park; Yongdo Kwak; Seol Ae Lee; Haeryun Lee; Hyeon Son; Sang Ki Park
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

6.  Relationship between Patient Demographic Characteristics, Valproic Acid Dosage and Clearance in Adult Iranian Patients.

Authors:  Tamara Aghebati; Mohsen Foroughipour; Mahmoud Reza Azarpazhooh; Naghme Mokhber; Mohammad Hasanzadeh Khayat; Naser Vahdati; Amir Hooshang Mohammadpour
Journal:  Iran J Basic Med Sci       Date:  2012-03       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.